AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate UpdateLandmark exclusive option and license deal with Takeda for ...
AC Immune reports FY24 EPS (51c), consensus (54c)
Reports FY24 revenue $27.3M, consensus $26.97M. Dr. Andrea Pfeifer, CEO of AC Immune (ACIU) SA, commented: “We significantly advanced our ...